Italia markets closed

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
6,57+0,09 (+1,39%)
Alla chiusura: 04:00PM EST
6,88 +0,31 (+4,72%)
Dopo ore: 07:56PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente6,48
Aperto6,41
Denaro6,50 x 1100
Lettera6,90 x 1000
Min-Max giorno6,37 - 6,72
Intervallo di 52 settimane4,21 - 22,22
Volume430.171
Media Volume826.898
Capitalizzazione431,564M
Beta (5 anni mensile)1,48
Rapporto PE (ttm)N/D
EPS (ttm)-0,32
Prossima data utili22 feb 2023 - 27 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,25
  • GlobeNewswire

    Codexis Announces Appointment of Sri Ryali as Chief Financial Officer

    REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company’s financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. “I am ex

  • GlobeNewswire

    Codexis Announces Appointment of H. Stewart Parker to Board of Directors

    REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. “Stewart’s deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background,

  • GlobeNewswire

    Codexis Provides Update on Prioritized Corporate Strategy

    REDWOOD CITY, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success. As part of this plan, the Company has decided to discontinue investment in certain internal development programs, expand investment in high potential development prog